Last reviewed · How we verify
Valsartan, Valsartan HCT
At a glance
| Generic name | Valsartan, Valsartan HCT |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients (PHASE4)
- Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP) (PHASE4)
- Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension (PHASE4)
- Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy (PHASE3)
- Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan, Valsartan HCT CI brief — competitive landscape report
- Valsartan, Valsartan HCT updates RSS · CI watch RSS
- Novartis portfolio CI